To investigate whether the improved outcomes are achieved via on-target effect of NAZ, we examined Aldh1a3 levels in NAZ-treated zebrafish melanomas in progressive, drug-resistant disease and found that Aldh1a3 clusters were absent (Figure 7F). The gene discussed is ALDH1A3; the disease is melanoma.